SDShaodong Dai

Shaodong Dai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shaodong Dai has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • John W. Kappler

    Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206

    7 shared publications
  • Philippa Marrack

    Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA

    7 shared publications
  • Frances Crawford

    Department of Biomedical Research, National Jewish Health, Denver, CO 80206, USA

    6 shared publications
  • Yang Wang

    Department of Biomedical Research, National Jewish Health , Denver, Colorado

    5 shared publications
  • Yang Wang

    Department of Biomedical Research, National Jewish Health, Denver, CO 80206, USA

    5 shared publications
  • Andrey Novikov

    Department of Biomedical Research, National Jewish Health , Denver, Colorado

    4 shared publications

Latest Publications

  • Open Access

    DksA inhibitors against intracellular and persistent Salmonella are effective in acute models of infection

    by Ju-Sim Kim, Vijay Kumar, Lin Liu, Yu J. Choi, Simona Senovaityte, Bruce D. McCollister, Nathan Wlodarchak, David J. Orlicky, Peter J. Rice, Shaodong Dai, et al.

    We are in dire need of antibiotics endowed with new mechanisms of action. The DksA protein regulates the transcription of genes involved in metabolism, translation, and virulence in Gram-negative bacteria. DksA is evolutionarily conserved among Gram-negative pathogens but is absent in humans. Here, we identified a conserved acidic pocket at the tip of the coiled-coil domain of DksA that is amenable for drug development. Our bioinformatics and experimental approaches identified N -(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide as a DksA inhibitor with moderate antimicrobial activity. Derivatization of the dimethoxyphenyl functionality and aliphatic linker of N -(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide generated several new chemical entities with excellent IC 50 values against DksA-regulated in vitro transcription and improved antimicrobial activity against Salmonella and several other Gram-negative bacteria. Our pharmacokinetic and pharmacodynamic evaluations indicate that the N -(4-phenylbutyl)-1H-1,2,4-triazole-3-carboxamide analog is absorbed in the gastrointestinal tract of rats and is distributed into viscera. The systemic administration of the N -(4-phenylbutyl)-1H-1,2,4-triazole-3-carboxamide analog protected mice against oral and systemic Salmonella infections while practically preventing the formation of microabscesses and necrotic foci in Salmonella -infected mice. Our investigations have identified a previously unknown class of antibiotics against the transcriptional regulator DksA that is endowed with antimicrobial activity against Gram-negative pathogens.


  • Open Access

    First-in-Class SAM-Competitive G9a Inhibitor FLAV-27 as a Disease-Modifying Therapy for Alzheimer’s Disease

    by Christian Griñán-Ferré, Aina Bellver-Sanchis, David Valle-Garcia, Carla Barbaraci, Fernando Romero-Beccera, Rohit Singh, Foteini Vasilopoulou, Alba Irisarri, Carmen Martinez-Fernandez, Juan Fafián-Labora, et al.

    Alzheimer’s disease (AD) is characterized by a progressive cognitive decline involving a multifactorial pathophysiology, including epigenetic dysregulation. Here, we report the discovery and preclinical validation of FLAV-27, a first-in-class, SAM-competitive, brain-penetrant and selective inhibitor of the histone methyltransferase G9a. Unlike prior G9a/GLP inhibitors, FLAV-27 exhibits subnanomolar potency, over 30-fold selectivity, and robust central nervous system bioavailability. Structural studies confirm a unique SAM-binding mode that confers superior specificity and avoids off-target effects. FLAV-27 reduces amyloid beta (Aβ) and p-tau aggregation and restores neuritic complexity in vitro. In Caenorhabditis elegans, it improves mobility, lifespan, and mitochondrial respiration. In mouse models of both late-onset AD (SAMP8) and early-onset AD (5xFAD), FLAV-27 rescues memory performance, social behavior, and synaptic structure. Multi-omics analyses reveal a global reprogramming of H3K9me2/H3K18me-mediated repression, reduced ferroptosis vulnerabilities, and normalization of AD-linked biomarkers, including SMOC1, H3K9me2, and p-Tau181, in the plasma and brain. Our findings position FLAV-27 as a promising epigenetic therapeutic with disease-modifying potential and translational biomarker alignment in AD.

  • Open Access

    Synovial fluid nickel and cobalt concentrations in patients with failed cobalt/chromium knee replacements

    by Karin Pacheco, Lan Chen, Richard Meehan, Lisa Barker, Jared M. Brown, Keegan Rogers, Shaodong Dai

    Background : Cobalt/chromium alloy is the most frequently used material in knee replacement hardware. It is composed of 60% cobalt, 30% chromium, 5% molybdenum, and contains from 0.5 - 2% nickel. We have found that nickel sensitization is an important cause of failed knee replacements in these patients. Despite such low percent concentrations in the alloy, whether nickel elutes from the implant material and become detectable in synovial fluid from cobalt/chromium knee replacements has never been measured. If so, such soluble material would be more available to trigger an immune inflammatory response. Methods : After obtaining written informed consent, we collected synovial fluid from the knees of patients with failed cobalt/chromium knee replacements, from those with other non-nickel containing implants, or those without implants with osteoarthritis or rheumatoid arthritis. We measured synovial fluid concentrations of nickel, cobalt, chromium, and molybdenum by inductively coupled plasma-mass spectrometry (ICP-MS). Results : Nickel and cobalt concentrations were significantly higher in patients with cobalt/chromium knee replacements, and virtually non-detectable in other non-nickel, non-cobalt implants or in other causes of knee arthritis. In those with failed cobalt/chromium knee hardware, nickel concentrations were also significantly higher in patients with failure due to nickel sensitization compared to those with other causes of failure. Conclusion : Despite low concentrations in cobalt/chromium alloy, nickel does elute from this material, is detectable in synovial fluid from failed cobalt/chromium knee replacements, and is significantly higher in nickel-sensitized patients with these failed implants. Elevated cobalt concentrations are also found in some of these patients.

  • Open Access

    CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope

    by Sarah A. Greaves, Avinash Ravindran, Radleigh G. Santos, Lan Chen, Michael T. Falta, Yang Wang, Angela M. Mitchell, Shaikh M. Atif, Douglas G. Mack, Alex N. Tinega, et al.

    Löfgren’s syndrome (LS) is an acute form of sarcoidosis characterized by a genetic association with HLA-DRB1*03 (HLA-DR3) and an accumulation of CD4+ T cells of unknown specificity in the bronchoalveolar lavage (BAL). Here, we screened related LS-specific TCRs for antigen specificity and identified a peptide derived from NAD-dependent histone deacetylase hst4 (NDPD) of Aspergillus nidulans that stimulated these CD4+ T cells in an HLA-DR3–restricted manner. Using ELISPOT analysis, a greater number of IFN-γ– and IL-2–secreting T cells in the BAL of DR3+ LS subjects compared with DR3+ control subjects was observed in response to the NDPD peptide. Finally, increased IgG antibody responses to A. nidulans NDPD were detected in the serum of DR3+ LS subjects. Thus, our findings identify a ligand for CD4+ T cells derived from the lungs of LS patients and suggest a role of A. nidulans in the etiology of LS.


  • Open Access

    Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer

    by Pengcheng Wei, Kimberly R. Jordan, Jonathan D. Buhrman, Jun Lei, Hexiang Deng, Philippa Marrack, Shaodong Dai, John W. Kappler, Jill E. Slansky, Lei Yin

    Significance: Tumor vaccines using modified self-antigens that structurally enhance T cell receptor–peptide–major histocompatibility complex interactions greatly improve a T cell protective response against the tumor’s unmodified self-antigen. X-ray crystal structures of these interactions explain how the native and modified peptides can interact with the same T cell receptor, but with different affinities and abilities to drive T cell proliferation and differentiation.


  • How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes

    by Yang Wang, Tomasz Sosinowski, Andrey Novikov, Frances Crawford, Janice White, Niyun Jin, Zikou Liu, Jinhao Zou, David Neau, Howard W. Davidson, et al.

    In type 1 diabetes, mouse and human CD4 + T cells recognize mutated and chimeric superagonist insulin B-chain epitopes similarly.


  • Open Access

    Hydrogen bonds are a primary driving force forde novoprotein folding. Corrigendum

    by Schuyler Lee, Chao Wang, Haolin Liu, Jian Xiong, Renee Jiji, Xia Hong, Xiaoxue Yan, Zhangguo Chen, Michal Hammel, Yang Wang, et al.

    The paper by Leeet al.[(2017).Acta Cryst.D73, 955–969] is withdrawn.


  • The Enzymatic and Structural Basis for Inhibition of Echinococcus granulosus Thioredoxin Glutathione Reductase by Gold(I)

    by Gustavo Salinas, Wei Gao, Yang Wang, Mariana Bonilla, Long Yu, Andrey Novikov, Veridiana G. Virginio, Henrique B. Ferreira, Marisol Vieites, Vadim N. Gladyshev, et al.

    Aims: New drugs are needed to treat flatworm infections that cause severe human diseases such as schistosomiasis. The unique flatworm enzyme thioredoxin glutathione reductase (TGR), structurally different from the human enzyme, is a key drug target. Structural studies of the flatworm Echinococcus granulosus TGR, free and complexed with Au I -MPO, a novel gold inhibitor, together with inhibition assays were performed. Results: Au I -MPO is a potent TGR inhibitor that achieves 75% inhibition at a 1:1 TGR:Au ratio and efficiently kills E. granulosus in vitro . The structures revealed salient insights: (i) unique monomer–monomer interactions, (ii) distinct binding sites for thioredoxin and the glutaredoxin (Grx) domain, (iii) a single glutathione disulfide reduction site in the Grx domain, (iv) rotation of the Grx domain toward the Sec-containing redox active site, and (v) a single gold atom bound to Cys 519 and Cys 573 in the Au I -TGR complex. Structural modeling suggests that these residues are involved in the stabilization of the Sec-containing C-terminus. Consistently, Cys→Ser mutations in these residues decreased TGR activities. Mass spectroscopy confirmed these cysteines are the primary binding site. Innovation: The identification of a primary site for gold binding and the structural model provide a basis for gold compound optimization through scaffold adjustments. Conclusions: The structural study revealed that TGR functions are achieved not only through a mobile Sec-containing redox center but also by rotation of the Grx domain and distinct binding sites for Grx domain and thioredoxin. The conserved Cys 519 and Cys 573 residues targeted by gold assist catalysis through stabilization of the Sec-containing redox center. Antioxid. Redox Signal . 27, 1491–1504.


  • Open Access

    C-terminal modification of the insulin B:11–23 peptide creates superagonists in mouse and human type 1 diabetes

    by Yang Wang, Tomasz Sosinowski, Andrey Novikov, Frances Crawford, David B. Neau, Junbao Yang, William W. Kwok, Philippa Marrack, John W. Kappler, Shaodong Dai

    A polymorphism at β57 in some major histocompatibility complex class II (MHCII) alleles of rodents and humans is associated with a high risk for developing type 1 diabetes (T1D). However, a highly diabetogenic insulin B chain epitope within the B:9–23 peptide is presented poorly by these alleles to a variety of mouse and human CD4 T cells isolated from either nonobese diabetic (NOD) mice or humans with T1D. We have shown for both species that mutations at the C-terminal end of this epitope dramatically improve presentation to these T cells. Here we present the crystal structures of these mutated peptides bound to mouse IAg7 and human HLA-DQ8 that show how the mutations function to improve T-cell activation. In both peptide binding grooves, the mutation of B:22R to E in the peptide changes a highly unfavorable side chain for the p9 pocket to an optimal one that is dependent on the β57 polymorphism, accounting for why these peptides bind much better to these MHCIIs. Furthermore, a second mutation of the adjacent B:21 (E to G) removes a side chain from the surface of the complex that is highly unfavorable for a subset of NOD mouse CD4 cells, thereby greatly enhancing their response to the complex. These results point out the similarities between the mouse and human responses to this B chain epitope in T1D and suggest there may be common posttranslational modifications at the C terminus of the peptide in vivo to create the pathogenic epitopes in both species. Significance Insulin is a target of CD4 T cells in type 1 diabetes in mice and humans. Why the major epitope in the insulin B chain is presented poorly to the diabetogenic CD4 T cells by the disease-associated major histocompatibility class II (MHCII) alleles has been highly debated. Here we present high-resolution mouse and human MHCII structures and T-cell functional data to show that C-terminal modifications of this epitope are required for binding and presentation in the appropriate position in the MHCII binding groove. These results suggest that pancreas-specific posttranslational modifications of this peptide may play a role in the induction of diabetes and explain how the pathogenic T cells escape deletion in the thymus.


  • Open Access

    Hydrogen bonds are a primary driving force forde novoprotein folding

    by Schuyler Lee, Chao Wang, Haolin Liu, Jian Xiong, Renee Jiji, Xia Hong, Xiaoxue Yan, Zhangguo Chen, Michal Hammel, Yang Wang, et al.

    The protein-folding mechanism remains a major puzzle in life science. Purified soluble activation-induced cytidine deaminase (AID) is one of the most difficult proteins to obtain. Starting from inclusion bodies containing a C-terminally truncated version of AID (residues 1–153; AID153), an optimizedin vitrofolding procedure was derived to obtain large amounts of AID153, which led to crystals with good quality and to final structural determination. Interestingly, it was found that the final refolding yield of the protein is proline residue-dependent. The difference in the distribution ofcisandtransconfigurations of proline residues in the protein after complete denaturation is a major determining factor of the final yield. A point mutation of one of four proline residues to an asparagine led to a near-doubling of the yield of refolded protein after complete denaturation. It was concluded that the driving force behind protein folding could not overcome thecis-to-transproline isomerization, orvice versa, during the protein-folding process. Furthermore, it was found that successful refolding of proteins optimally occurs at high pH values, which may mimic protein foldingin vivo. It was found that high pH values could induce the polarization of peptide bonds, which may trigger the formation of protein secondary structures through hydrogen bonds. It is proposed that a hydrophobic environment coupled with negative charges is essential for protein folding. Combined with our earlier discoveries on protein-unfolding mechanisms, it is proposed that hydrogen bonds are a primary driving force forde novoprotein folding.